Drug Safety

2012 - 2025

Current editor(s): Nitin Joshi

From Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().

Access Statistics for this journal.
Is something missing from the series or not right? See the RePEc data check for the archive and series.

Volume 39, issue 12, 2016

On Designs for Vaccine Surveillance pp. 1161-1162

Robert W. Platt

Treatment-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: A Comprehensive Review of Current Evidence and Future Needs pp. 1163-1174

Emanuele D’Amico, Aurora Zanghì, Carmela Leone, Hayrettin Tumani and Francesco Patti

Risk–Benefit Profile of Direct-Acting Oral Anticoagulants in Established Therapeutic Indications: An Overview of Systematic Reviews and Observational Studies pp. 1175-1187

Emanuel Raschi, Matteo Bianchin, Walter Ageno, Roberto De Ponti and Fabrizio De Ponti

Completeness of Spontaneous Adverse Drug Reaction Reports Sent by General Practitioners to a Regional Pharmacovigilance Centre: A Descriptive Study pp. 1189-1195

Geneviève Durrieu, Julien Jacquot, Mathilde Mège, Emmanuelle Bondon-Guitton, Vanessa Rousseau, François Montastruc and Jean-Louis Montastruc

Vaccine Case–Population: A New Method for Vaccine Safety Surveillance pp. 1197-1209

Hélène Théophile, Nicholas Moore, Philip Robinson, Bernard Bégaud and Antoine Pariente

Estimating Herbal Product Authentication and Adulteration in India Using a Vouchered, DNA-Based Biological Reference Material Library pp. 1211-1227

Dhivya Shanmughanandhan, Subramanyam Ragupathy, Steven G. Newmaster, Saravanan Mohanasundaram and Ramalingam Sathishkumar

The Risk of Achilles or Biceps Tendon Rupture in New Statin Users: A Propensity Score-Matched Sequential Cohort Study pp. 1229-1237

Julia Spoendlin, J. Bradley Layton, Mallika Mundkur, Christian Meier, Susan S. Jick and Christoph R. Meier

Knowledge of Adverse Drug Reaction Reporting Among Healthcare Professionals in Bhutan: A Cross-Sectional Survey pp. 1239-1250

Choki Dorji, Pramote Tragulpiankit, Arthorn Riewpaiboon and Tashi Tobgay

Volume 39, issue 11, 2016

National ADR Monitoring System in China pp. 1043-1051

Yongfang Hou, Xinling Li, Guizhi Wu and Xiaofei Ye

Drug–Drug Interactions, Effectiveness, and Safety of Hormonal Contraceptives in Women Living with HIV pp. 1053-1072

Kimberly K. Scarsi, Kristin M. Darin, Catherine A. Chappell, Stephanie M. Nitz and Mohammed Lamorde

Tyrosine Kinase Inhibitor-Induced Interstitial Lung Disease: Clinical Features, Diagnostic Challenges, and Therapeutic Dilemmas pp. 1073-1091

Rashmi R. Shah

Pattern of Onset and Risk Factors for Peripheral Oedema During Vildagliptin Use: Analysis from the Vildagliptin Prescription–Event Monitoring Study in England pp. 1093-1104

Deborah Layton, Abigail L. Coughtrie, Naseer Qayum and Saad A. W. Shakir

Patient Reporting of Adverse Drug Reactions: An International Survey of National Competent Authorities’ Views and Needs pp. 1105-1116

Cristiano Matos, Linda Härmark and Florence Hunsel

A Survey of Adverse Event Reporting Practices Among US Healthcare Professionals pp. 1117-1127

Stella Stergiopoulos, Carrie A. Brown, Thomas Felix, Gustavo Grampp and Kenneth A. Getz

Prevention of Medication Errors in Hospitalized Patients: The Japan Adverse Drug Events Study pp. 1129-1137

Chihiro Noguchi, Mio Sakuma, Yoshinori Ohta, David W. Bates and Takeshi Morimoto

Association Between the Occurrence of Adverse Drug Events and Modification of First-Line Highly Active Antiretroviral Therapy in Ghanaian HIV Patients pp. 1139-1149

Raymond A. Tetteh, Edmund T. Nartey, Margaret Lartey, Aukje K. Mantel-Teeuwisse, Hubert G. M. Leufkens, Barbara A. Yankey and Alexander N. O. Dodoo

Comment on: “Safety and Tolerability of Pharmacological Treatment of Alcohol Dependence: Comprehensive Review of Evidence” pp. 1151-1152

Alain Braillon

Authors’ Reply to Alain Braillon’s Comment on “Safety and Tolerability of Pharmacological Treatment of Alcohol Dependence: Comprehensive Review of Evidence” pp. 1153-1154

Julia M. A. Sinclair, Sophia E. Chambers and David S. Baldwin

Volume 39, issue 10, 2016

Patient-Reported Safety Information: A Renaissance of Pharmacovigilance? pp. 883-890

Linda Härmark, June Raine, Hubert Leufkens, I. Ralph Edwards, Ugo Moretti, Viola Macolic Sarinic and Agnes Kant

Pacific Island Pharmacovigilance: The Need for a Different Approach pp. 891-894

John McEwen, Lasse S. Vestergaard and Amanda L. C. Sanburg

Causality Assessment in Premarketing Drug Clinical Trials: Regulatory Evolution in the USA and Ongoing Concerns pp. 895-901

Stephen A. Goldman

Neonatal Adaptation Issues After Maternal Exposure to Prescription Drugs: Withdrawal Syndromes and Residual Pharmacological Effects pp. 903-924

Irma Convertino, Alice Capogrosso Sansone, Alessandra Marino, Maria T. Galiulo, Stefania Mantarro, Luca Antonioli, Matteo Fornai, Corrado Blandizzi and Marco Tuccori

Hepatic Safety of Atypical Antipsychotics: Current Evidence and Future Directions pp. 925-943

Mahmoud Slim, Inmaculada Medina-Caliz, Andres Gonzalez-Jimenez, M. Rosario Cabello, Fermin Mayoral-Cleries, M. Isabel Lucena and Raul J. Andrade

Neuropsychiatric Effects of HIV Antiviral Medications pp. 945-957

Glenn J. Treisman and Olivia Soudry

Targeted Spontaneous Reporting: Assessing Opportunities to Conduct Routine Pharmacovigilance for Antiretroviral Treatment on an International Scale pp. 959-976

Beth Rachlis, Rakhi Karwa, Celia Chema, Sonak Pastakia, Sten Olsson, Kara Wools-Kaloustian, Beatrice Jakait, Mercy Maina, Marcel Yotebieng, Nagalingeswaran Kumarasamy, Aimee Freeman, Nathalie de Rekeneire, Stephany N. Duda, Mary-Ann Davies and Paula Braitstein

Innovative Digital Tools and Surveillance Systems for the Timely Detection of Adverse Events at the Point of Care: A Proof-of-Concept Study pp. 977-988

Christian Hoppe, Patrick Obermeier, Susann Muehlhans, Maren Alchikh, Lea Seeber, Franziska Tief, Katharina Karsch, Xi Chen, Sindy Boettcher, Sabine Diedrich, Tim Conrad, Bron Kisler and Barbara Rath

Volume 39, issue 9, 2016

The Patient’s Voice in Pharmacovigilance: Pragmatic Approaches to Building a Patient-Centric Drug Safety Organization pp. 779-785

Meredith Y. Smith and Isma Benattia

Benefit–Risk Assessment of Fish Oil in Preventing Cardiovascular Disease pp. 787-799

Bill Lands

Drug-Induced Liver Injury: Highlights from a Review of the 2015 Literature pp. 801-821

Philip Sarges, Joshua M Steinberg and James H Lewis

Benefit and Risk of Tofacitinib in the Treatment of Rheumatoid Arthritis: A Focus on Herpes Zoster pp. 823-840

Kunihiro Yamaoka

Drug Interactions of Direct-Acting Oral Anticoagulants pp. 841-845

John Leonard Fitzgerald and Laurence Guy Howes

Adverse-Drug-Reaction-Related Hospitalisations in Developed and Developing Countries: A Review of Prevalence and Contributing Factors pp. 847-857

Mulugeta Tarekegn Angamo, Leanne Chalmers, Colin M. Curtain and Luke R. E. Bereznicki

Active Surveillance versus Spontaneous Reporting for First-Line Antiretroviral Medicines in Namibia: A Cost–Utility Analysis pp. 859-872

Marita Mann, Assegid Mengistu, Johannes Gaeseb, Evans Sagwa, Greatjoy Mazibuko, Joseph B. Babigumira, Louis P. Garrison and Andy Stergachis

Drug Safety Monitoring in Children: Performance of Signal Detection Algorithms and Impact of Age Stratification pp. 873-881

Osemeke U. Osokogu, Caitlin Dodd, Alexandra Pacurariu, Florentia Kaguelidou, Daniel Weibel and Miriam C. J. M. Sturkenboom

Volume 39, issue 8, 2016

Contemporary Reflections on the Safety of Long-Term Aspirin Treatment for the Secondary Prevention of Cardiovascular Disease pp. 715-727

Alexander C. Fanaroff and Matthew T. Roe

Diagnosis and Management of Drug-Induced Liver Injury (DILI) in Patients with Pre-Existing Liver Disease pp. 729-744

Rolf Teschke and Gaby Danan

Age at First Rotavirus Vaccination and Risk of Intussusception in Infants: A Public Health Modeling Analysis pp. 745-748

Chee Fu Yung, Chia Yin Chong and Koh Cheng Thoon

Risk of Liver Injury Associated with Green Tea Extract in SLIMQUICK® Weight Loss Products: Results from the DILIN Prospective Study pp. 749-754

Elizabeth X. Zheng, Simona Rossi, Robert J. Fontana, Raj Vuppalanchi, Jay H. Hoofnagle, Ikhlas Khan and Victor J. Navarro

Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis pp. 755-762

Megan E. B. Clowse, Steven R. Feldman, John D. Isaacs, Alexandra B. Kimball, Vibeke Strand, Richard B. Warren, Daniel Xibillé, Yan Chen, Donald Frazier, Jamie Geier, James Proulx and Amy Marren

Artesunate/Amodiaquine-Induced Acute Extrapyramidal Reactions in Children and Younger Adults: Case Series Assessment pp. 763-768

Mulugeta Russom, Dawit Tesfai, Semere Gebregiorgis, Abdulmumini Usman, Selam Mihreteab, Iyassu Bahta, Elsa Mekonnen, Selamawit Ghebrehiwet and Gelila Abrham

The Impact of Experiencing Adverse Drug Reactions on the Patient’s Quality of Life: A Retrospective Cross-Sectional Study in the Netherlands pp. 769-776

Leàn Rolfes, Florence Hunsel, Katja Taxis and Eugène Puijenbroek

Is Earlier Signal Detection Always Better? pp. 777-778

Alan M. Hochberg and Stella Stergiopoulos

Volume 39, issue 7, 2016

Pharmacokinetics, Efficacy, and Safety of Hepatitis C Virus Drugs in Patients with Liver and/or Renal Impairment pp. 589-611

Elise J. Smolders, Clara T. M. M. Kanter, Bart Hoek, Joop E. Arends, Joost P. H. Drenth and David M. Burger

Neurocognitive Adverse Effects of Anesthesia in Adults and Children: Gaps in Knowledge pp. 613-626

Christopher G. Ward and Roderic G. Eckenhoff

Safety and Tolerability of Pharmacological Treatment of Alcohol Dependence: Comprehensive Review of Evidence pp. 627-645

Julia M. A. Sinclair, Sophia E. Chambers, Celia J. Shiles and David S. Baldwin

Volume 39, issue 6, 2016

Medication Errors: New EU Good Practice Guide on Risk Minimisation and Error Prevention pp. 491-500

Thomas Goedecke, Kathryn Ord, Victoria Newbould, Sabine Brosch and Peter Arlett

Safety Considerations with Dual Bronchodilator Therapy in COPD: An Update pp. 501-508

Maria Gabriella Matera, Paola Rogliani, Luigino Calzetta and Mario Cazzola

The Safety of Prochlorperazine in Children: A Systematic Review and Meta-Analysis pp. 509-516

Melissa Lau Moon Lin, Paula D. Robinson, Jacqueline Flank, Lillian Sung and L. Lee Dupuis

Volume 39, issue 5, 2016

Measuring Signal Detection Performance: Can We Trust Negative Controls and Do We Need Them? pp. 371-373

Jim Slattery

Maximizing the Post-Approval Safety of Flibanserin: A Role for Regulators, Clinicians, and Patients pp. 375-380

Sheriza N. Baksh, Walid F. Gellad and G. Caleb Alexander

Side Effects and Efficacy of Neuraxial Opioids in Pregnant Patients at Delivery: A Comprehensive Review pp. 381-399

Sarah Armstrong and Roshan Fernando

Dipeptidyl Peptidase (DPP)-4 Inhibitor-Induced Arthritis/Arthralgia: A Review of Clinical Cases pp. 401-407

Annamaria Mascolo, Concetta Rafaniello, Liberata Sportiello, Maurizio Sessa, Daniela Cimmaruta, Francesco Rossi and Annalisa Capuano

Safety Profile of Atorvastatin 80 mg: A Meta-Analysis of 17 Randomized Controlled Trials in 21,910 Participants pp. 409-419

Haixia Li, Cailian Wang, Shuo Zhang, Sihao Sun, Ruifei Li, Meijuan Zou and Gang Cheng

Evidence of Misclassification of Drug–Event Associations Classified as Gold Standard ‘Negative Controls’ by the Observational Medical Outcomes Partnership (OMOP) pp. 421-432

Manfred Hauben, Jeffrey K. Aronson and Robin E. Ferner

An Integrative Data Science Pipeline to Identify Novel Drug Interactions that Prolong the QT Interval pp. 433-441

Tal Lorberbaum, Kevin J. Sampson, Raymond L. Woosley, Robert S. Kass and Nicholas P. Tatonetti

Social Media Listening for Routine Post-Marketing Safety Surveillance pp. 443-454

Gregory E. Powell, Harry A. Seifert, Tjark Reblin, Phil J. Burstein, James Blowers, J. Alan Menius, Jeffery L. Painter, Michele Thomas, Carrie E. Pierce, Harold W. Rodriguez, John S. Brownstein, Clark C. Freifeld, Heidi G. Bell and Nabarun Dasgupta

Allergy-Like Immediate Reactions with Herbal Medicines: A Retrospective Study Using Data from VigiBase® pp. 455-464

Jitka Pokladnikova, Ronald H. B. Meyboom, Ricarda Meincke, David Niedrig and Stefan Russmann

Comment on: “Drug-Induced Hyperglycaemia and Diabetes” pp. 465-466

Jean-Louis Montastruc, Leila Chebane and Haleh Bagheri

Authors’ Reply to Montastruc et al.: “Drug-Induced Hyperglycaemia and Diabetes” pp. 467-467

Neila Fathallah, Raoudha Slim, Sofiene Larif, Houssem Hmouda and Chaker Ben Salem

Volume 39, issue 4, 2016

Vulnerable Patients and Potential Harms: The Contribution of Observational Research pp. 277-280

Deborah Layton

Pharmacovigilance is … Vigilance pp. 281-285

I. Ralph Edwards and Rachida Soulayamani Bencheikh

Comparative Safety and Tolerability of Prostacyclins in Pulmonary Hypertension pp. 287-294

Caroline O’Connell, David Amar, Athénaïs Boucly, Laurent Savale, Xavier Jaïs, Marie-Camille Chaumais, David Montani, Marc Humbert, Gérald Simonneau and Olivier Sitbon

Quantitative Risk–Benefit Analysis of Probiotic Use for Irritable Bowel Syndrome and Inflammatory Bowel Disease pp. 295-305

William E. Bennett

Risk of Seizures Associated with Antidepressant Use in Patients with Depressive Disorder: Follow-up Study with a Nested Case–Control Analysis Using the Clinical Practice Research Datalink pp. 307-321

Marlene Bloechliger, Alessandro Ceschi, Stephan Rüegg, Hugo Kupferschmidt, Stephan Kraehenbuehl, Susan S. Jick, Christoph R. Meier and Michael Bodmer

Safety of Intranasal Quadrivalent Live Attenuated Influenza Vaccine (QLAIV) in Children and Adolescents: A Pilot Prospective Cohort Study in England pp. 323-333

Rhian McNaughton, Elizabeth Lynn, Vicki Osborne, Abigail Coughtrie, Deborah Layton and Saad Shakir

Adverse Drug Reaction Reporting in Africa and a Comparison of Individual Case Safety Report Characteristics Between Africa and the Rest of the World: Analyses of Spontaneous Reports in VigiBase® pp. 335-345

Haggar H. Ampadu, Jarno Hoekman, Marieke L. Bruin, Shanthi N. Pal, Sten Olsson, Daniele Sartori, Hubert G. M. Leufkens and Alexander N. O. Dodoo

Sequence Symmetry Analysis as a Signal Detection Tool for Potential Heart Failure Adverse Events in an Administrative Claims Database pp. 347-354

Izyan A. Wahab, Nicole L. Pratt, Lisa Kalisch Ellett and Elizabeth E. Roughead

Performance of Stratified and Subgrouped Disproportionality Analyses in Spontaneous Databases pp. 355-364

Suzie Seabroke, Gianmario Candore, Kristina Juhlin, Naashika Quarcoo, Antoni Wisniewski, Ramin Arani, Jeffery Painter, Philip Tregunno, G. Niklas Norén and Jim Slattery

Comment on ‘The Contribution of National Spontaneous Reporting Systems to Detect Signals of Torsadogenicity: Issues Emerging from the ARITMO Project’ pp. 365-365

Alain Braillon

Authors’ Reply to Alain Braillon’s Comment on “The Contribution of National Spontaneous Reporting Systems to Detect Signals of Torsadogenicity: Issues Emerging from the ARITMO Project” pp. 367-368

Emanuel Raschi, Elisabetta Poluzzi, Francesco Salvo, Ugo Moretti and Fabrizio Ponti

Erratum to: Renal and Bone Adverse Effects of a Tenofovir-Based Regimen in the Treatment of HIV-Infected Children: A Systematic Review pp. 369-369

Rose I. Okonkwo, Anita E. Weidmann and Emmanuel E. Effa

Volume 39, issue 3, 2016

Risk of Inflammatory Bowel Disease with Oral Contraceptives and Menopausal Hormone Therapy: Current Evidence and Future Directions pp. 193-197

Hamed Khalili

Hepatotoxicity Associated with the Use of Anti-TNF-α Agents pp. 199-208

Joshua B. French, Maurizio Bonacini, Marwan Ghabril, David Foureau and Herbert L. Bonkovsky

Renal and Bone Adverse Effects of a Tenofovir-Based Regimen in the Treatment of HIV-Infected Children: A Systematic Review pp. 209-218

Rose I. Okonkwo, Anita E. Weidmann and Emmanuel E. Effa

Post-Marketing Benefit–Risk Assessment of Rotavirus Vaccination in Japan: A Simulation and Modelling Analysis pp. 219-230

Edouard Ledent, Alfons Lieftucht, Hubert Buyse, Keiji Sugiyama, Michael Mckenna and Katsiaryna Holl

Social Media Mining for Toxicovigilance: Automatic Monitoring of Prescription Medication Abuse from Twitter pp. 231-240

Abeed Sarker, Karen O’Connor, Rachel Ginn, Matthew Scotch, Karen Smith, Dan Malone and Graciela Gonzalez

Clinicians’ Reports in Electronic Health Records Versus Patients’ Concerns in Social Media: A Pilot Study of Adverse Drug Reactions of Aspirin and Atorvastatin pp. 241-250

Maxim Topaz, Kenneth Lai, Neil Dhopeshwarkar, Diane L. Seger, Roee Sa’adon, Foster Goss, Ronen Rozenblum and Li Zhou

A Method for the Minimization of Competition Bias in Signal Detection from Spontaneous Reporting Databases pp. 251-260

Mickael Arnaud, Francesco Salvo, Ismaïl Ahmed, Philip Robinson, Nicholas Moore, Bernard Bégaud, Pascale Tubert-Bitter and Antoine Pariente

Use of Prescription Drug Samples in the USA: A Descriptive Study with Considerations for Pharmacoepidemiology pp. 261-270

Christian Hampp, Patty Greene and Simone P. Pinheiro

The 9th International Congress on Cutaneous Adverse Drug Reactions at the 23rd World Congress of Dermatology in Vancouver, 2015 pp. 271-276

Roni P. Dodiuk-Gad, Cristina Olteanu, Wen-Hung Chung and Neil H. Shear

Volume 39, issue 2, 2016

Mortality Risk of Hypnotics: Strengths and Limits of Evidence pp. 93-107

Daniel F. Kripke

Appropriate Polypharmacy and Medicine Safety: When Many is not Too Many pp. 109-116

Cathal A. Cadogan, Cristín Ryan and Carmel M. Hughes

Testosterone Replacement Therapy and Mortality in Older Men pp. 117-130

G. I. Hackett

Tools for Assessing Potential Significance of Pharmacist Interventions: A Systematic Review pp. 131-146

Thi-Ha Vo, Bruno Charpiat, Claire Catoire, Michel Juste, Renaud Roubille, François-Xavier Rose, Sébastien Chanoine, Jean-Luc Bosson, Ornella Conort, Benoît Allenet and Pierrick Bedouch

Safety of Dalbavancin in the Treatment of Skin and Skin Structure Infections: A Pooled Analysis of Randomized, Comparative Studies pp. 147-157

Michael W. Dunne, George H. Talbot, Helen W. Boucher, Mark Wilcox and Sailaja Puttagunta

Adverse Drug Reactions Reported to a National HIV & Tuberculosis Health Care Worker Hotline in South Africa: Description and Prospective Follow-Up of Reports pp. 159-169

Christine Njuguna, Annemie Stewart, Johannes P. Mouton, Marc Blockman, Gary Maartens, Annoesjka Swart, Briony Chisholm, Jackie Jones, Mukesh Dheda, Ehimario U. Igumbor and Karen Cohen

Consumer Understanding, Preferences, and Responses to Different Versions of Drug Safety Messages in the United States: A Randomized Controlled Trial pp. 171-184

Lauren McCormack, R. Craig Lefebvre, Carla Bann, Olivia Taylor and Paula Rausch

Traceability of Biologics in The Netherlands: An Analysis of Information-Recording Systems in Clinical Practice and Spontaneous ADR Reports pp. 185-192

Kevin Klein, Joep H. G. Scholl, Niels S. Vermeer, André W. Broekmans, Eugène P. Puijenbroek, Marie L. Bruin and Pieter Stolk

Volume 39, issue 1, 2016

What Is the Plural of a ‘Yellow’ Anecdote? pp. 1-3

Stephen J. W. Evans

Reversal Strategies for NOACs: State of Development, Possible Clinical Applications and Future Perspectives pp. 5-13

Steen Husted, Freek W. A. Verheugt and Willemijn J. Comuth

Advances in the Pharmacogenomics of Adverse Drug Reactions pp. 15-27

Susannah L. Collins, Daniel F. Carr and Munir Pirmohamed

An Empirical Approach to Explore the Relationship Between Measures of Disproportionate Reporting and Relative Risks from Analytical Studies pp. 29-43

Miguel-Angel Maciá-Martínez, Francisco J. Abajo, Gilly Roberts, Jim Slattery, Bharat Thakrar and Antoni F. Z. Wisniewski

Feasibility of Prioritizing Drug–Drug-Event Associations Found in Electronic Health Records pp. 45-57

Juan M. Banda, Alison Callahan, Rainer Winnenburg, Howard R. Strasberg, Aurel Cami, Ben Y. Reis, Santiago Vilar, George Hripcsak, Michel Dumontier and Nigam Haresh Shah

The Contribution of National Spontaneous Reporting Systems to Detect Signals of Torsadogenicity: Issues Emerging from the ARITMO Project pp. 59-68

Emanuel Raschi, Elisabetta Poluzzi, Francesco Salvo, Ariola Koci, Marc Suling, Stefania Antoniazzi, Luisella Perina, Lorna Hazell, Ugo Moretti, Miriam Sturkenboom, Edeltraut Garbe, Antoine Pariente and Fabrizio Ponti

Psychiatric Disorders and Montelukast in Children: A Disproportionality Analysis of the VigiBase® pp. 69-78

Ana Aldea Perona, Mar García-Sáiz and Emilio Sanz Álvarez

The Association Between Potentially Inappropriate Prescribing and Medication-Related Hospital Admissions in Older Patients: A Nested Case Control Study pp. 79-87

C. A. K. Stelt, A. M. A. Vermeulen Windsant- van den Tweel, A. C. G. Egberts, P. M. L. A. Bemt, A. J. Leendertse, W. A. J. J. Hermens, R. J. Marum and H. J. Derijks

Comment on: “Indigenous Medicine Use for Sex Selection During Pregnancy and Risk of Congenital Malformations: A Population-Based Case–Control Study in Haryana, India” pp. 89-90

Sibel Yöntem, Belgin Maden-Tastan and Yusuf Cem Kaplan

Authors’ Reply to Sibel Yöntem and Colleagues’ Comment on “Indigenous Medicine Use for Sex Selection During Pregnancy and Risk of Congenital Malformations: A Population-Based Case-Control Study in Haryana, India” pp. 91-92

Sutapa Bandyopadhyay Neogi, Preeti H. Negandhi, Ravi Kant Gupta, Abhijit Ganguli, Sanjay Zodpey, Amarjeet Singh and Rakesh Gupta